1. Home
  2. HBB vs VYGR Comparison

HBB vs VYGR Comparison

Compare HBB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

N/A

Current Price

$16.78

Market Cap

210.8M

ML Signal

N/A

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.41

Market Cap

232.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
VYGR
Founded
1904
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.8M
232.4M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
HBB
VYGR
Price
$16.78
$4.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.00
AVG Volume (30 Days)
21.1K
478.6K
Earning Date
11-05-2025
11-10-2025
Dividend Yield
2.87%
N/A
EPS Growth
24.53
N/A
EPS
2.34
N/A
Revenue
$607,430,000.00
$31,316,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$71.78
P/E Ratio
$7.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$2.65
52 Week High
$21.20
$6.55

Technical Indicators

Market Signals
Indicator
HBB
VYGR
Relative Strength Index (RSI) 64.98 54.64
Support Level $15.24 $3.74
Resistance Level $16.85 $4.51
Average True Range (ATR) 0.69 0.21
MACD 0.12 0.06
Stochastic Oscillator 100.00 85.59

Price Performance

Historical Comparison
HBB
VYGR

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: